Australia Immunoassay For Neurological Biomarkers Market Size & Outlook
Australia immunoassay for neurological biomarkers market, 2018-2030 (US$M)
Related Markets
Australia immunoassay for neurological biomarkers market highlights
- The Australia immunoassay for neurological biomarkers market generated a revenue of USD 182.6 million in 2023 and is expected to reach USD 460.3 million by 2030.
- The Australia market is expected to grow at a CAGR of 14.1% from 2024 to 2030.
- In terms of segment, alzheimer's disease was the largest revenue generating application in 2023.
- Alzheimer's Disease is the most lucrative application segment registering the fastest growth during the forecast period.
Immunoassay for neurological biomarkers market data book summary
| Market revenue in 2023 | USD 182.6 million |
| Market revenue in 2030 | USD 460.3 million |
| Growth rate | 14.1% (CAGR from 2023 to 2030) |
| Largest segment | Alzheimer's disease |
| Fastest growing segment | Alzheimer's Disease |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
| Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
Other key industry trends
- In terms of revenue, Australia accounted for 2.3% of the global immunoassay for neurological biomarkers market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan immunoassay for neurological biomarkers market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 419.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Immunoassay For Neurological Biomarkers Market Scope
Immunoassay For Neurological Biomarkers Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia immunoassay for neurological biomarkers market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 35.87% in 2023. Horizon Databook has segmented the Australia immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
The Australian immunoassays for neurological biomarkers market is expected to witness significant growth owing to research collaborations and favorable government initiatives. In January 2021, scientists from the University of South Australia developed a test for the prediction of mood disorders, based on the detection of level of a specific protein found in the brain.
The assay kit developed by the scientists can accurately distinguish between these proteins. Moreover, growing geriatric population is likely to drive the market in Australia. According to the Australian Institute of Health and Welfare, in 2020, over 4.2 million people, or 16% of the country’s total population, were aged 65 years and above, leading to an increase in disease burden.
For instance, Dementia Australia is conducting a study, titled Australian Imaging Biomarkers and Lifestyle Study Ageing (AIBL), which aims to develop tests that help early diagnosis of Alzheimer’s disease before the appearance of initial symptoms, and new treatment for prevention of diseases.
Reasons to subscribe to Australia immunoassay for neurological biomarkers market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia immunoassay for neurological biomarkers market databook
-
Our clientele includes a mix of immunoassay for neurological biomarkers market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia immunoassay for neurological biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Australia immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia immunoassay for neurological biomarkers market size, by application, 2018-2030 (US$M)
Australia Immunoassay For Neurological Biomarkers Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
